China SXT Pharmaceuticals, Inc. Announces Share Re-classification

Rhea-AI Summary

China SXT Pharmaceuticals (Nasdaq: SXTC) announced a share re-classification effective March 24, 2026, with Class A Ordinary Shares trading under SXTC on Nasdaq. Shareholders approved in a July 28, 2025 meeting creating unlimited Class B shares with 50 votes per share and redesignating existing shares as Class A.

The re-classification became effective upon filing the amended charter with the British Virgin Islands Companies Registry; nominee-held shares will be automatically adjusted. Contact brokers or Transhare Corporation for questions.

Positive

• Class B shares carry 50 votes per share
• Dual-class structure enables governance continuity for key holders
• Automated adjustment for nominee-held shares at market open

Negative

• Company authorized an unlimited number of new shares
• Dual-class structure may increase shareholder control concentration
• Potential dilution risk if additional shares are issued

Key Figures

Class B voting power: 50 votes per share Current share price: $1.40 52-week high: $1,046.985 +5 more

8 metrics

Class B voting power 50 votes per share Rights of newly created Class B Ordinary Shares

Current share price $1.40 Price on publication date vs 52-week low

52-week high $1,046.985 Pre-news 52-week high level

Share consolidation ratio 1-for-150 Class A share consolidation effective Feb 3, 2026

Registered offering size $10,000,000 Expected gross proceeds from Jan 9, 2026 direct offering

Offering price $0.15 per share Price for 66,666,666 Class A shares in Jan 9, 2026 offering

F-3 shelf capacity $600,000,000 Maximum aggregate offering price under Form F-3 filed Nov 10, 2025

Net proceeds $9,110,000 Net from offering detailed in Jan 13, 2026 Form 6-K

Market Reality Check

Price: $1.40 Vol: Volume 27,666 is at 0.77x...

normal vol

$1.40 Last Close

Volume Volume 27,666 is at 0.77x the 20-day average of 35,840 shares, indicating subdued trading ahead of the re-classification. normal

Technical Shares at $1.40 are trading well below the 200-day MA of $180.51 and sit at the 52-week low, down 99.87% vs the $1,046.99 52-week high.

Peers on Argus

SXTC was down 6.04% with modest volume. Sector peers showed mixed performance: D...

1 Up 1 Down

SXTC was down 6.04% with modest volume. Sector peers showed mixed performance: DERM -4.88%, TKNO -3.13%, BIOA -7.52%, while OGI slipped -0.73% and IRWD rose 4.26% in momentum scans. With peers moving both up and down and no same-day peer news, SXTC’s move appears more stock-specific than sector-driven.

Historical Context

4 past events · Latest: Jan 30 (Negative)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 30	Share consolidation	Negative	-38.0%	Announced 1-for-150 consolidation of Class A shares effective February 3, 2026.
Jan 15	Strategic AI initiative	Positive	+10.2%	Unveiled AI Insight Initiative for TCM supply chain transparency and stability.
Jan 09	Registered offering	Negative	-87.9%	Announced $10M registered direct offering of 66,666,666 shares or pre-funded warrants.
Jan 08	AI strategy expansion	Positive	-37.5%	Announced AI Insights Initiative for portfolio optimization and AI-supported clinics.

Pattern Detected

Recent corporate actions such as offerings and share consolidation were followed by sharp negative price reactions, while AI-related strategic initiatives saw more mixed to positive responses.

Recent Company History

Over the last few months, SXTC has focused on balance sheet and strategic repositioning. A registered direct offering in January 2026 and a 1-for-150 share consolidation on February 3, 2026 both coincided with steep declines of -87.92% and -38%, respectively. In contrast, AI-focused initiatives on January 8 and January 15, 2026 produced more mixed reactions, including a 10.18% gain. Today’s share re-classification continues the theme of structural capital and governance changes following recent financing and consolidation steps.

Regulatory & Risk Context

Active S-3 Shelf · $600,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$600,000,000 registered capacity

An effective Form F-3 shelf filed on Nov 10, 2025 allows SXTC to offer up to $600,000,000 of securities, with at least one 424B5 usage on Jan 12, 2026. This provides substantial flexibility for future capital raises via equity, debt, warrants, rights, or units, subject to public float constraints under General Instruction I.B.5.

Market Pulse Summary

This announcement formalizes a dual-class structure, re-designating existing shares as Class A and c...

Analysis

This announcement formalizes a dual-class structure, re-designating existing shares as Class A and creating high-vote Class B Ordinary Shares with 50 votes each. It follows a period of substantial capital activity, including a registered offering and a 1-for-150 consolidation. Investors may focus on how voting power is allocated, potential future issuance under the $600,000,000 Form F-3 shelf, and whether further structural changes affect dilution, control, or alignment with minority shareholders.

Key Terms

dual class share structure, class b ordinary shares, memorandum and articles of association, companies registry, +1 more

5 terms

dual class share structure financial

"shareholders approved a change to the Company’s authorized share capital to establish a dual class share structure"

A dual class share structure is a setup where a company issues two (or more) types of shares that carry different voting rights—one class gives founders or insiders most of the voting power while the other class offers the same financial upside but little or no say in decisions. For investors this matters because it separates ownership of returns from control: you can share in profits like a regular shareholder but have limited influence over strategy, similar to owning a stake in a restaurant without a vote on the menu.

class b ordinary shares financial

"creating a new class of shares consisting of unlimited Class B Ordinary Shares, which entitle the holder to fifty (50) votes"

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

memorandum and articles of association regulatory

"effective upon filing of the Amended and Restated Memorandum and Articles of Association with the Companies Registry"

Memorandum and articles of association are the founding legal documents of a company: the memorandum sets out the company’s basic purpose and scope, while the articles act as its internal rulebook detailing how the company is run, who has what powers, and how decisions are made. For investors these documents matter because they define ownership rights, voting rules, limits on activities, and procedures for major changes—like a contract and rulebook that determine how their investment can be used and protected.

companies registry regulatory

"with the Companies Registry of the British Virgin Islands by the Company."

A companies registry is an official government database that records basic legal and ownership details about businesses, such as their registered name, address, directors, and filing history. For investors it acts like a company’s public ID card and file cabinet—helping verify who runs the business, whether filings are up to date, and exposing legal or structural risks that could affect value or trustworthiness.

transfer agent financial

"or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122."

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

AI-generated analysis. Not financial advice.

TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that upon the market opening on March 24, 2026, the Company’s Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol “SXTC”.

On July 28, 2025, the Company held a special meeting of shareholders (the “Meeting”). At the Meeting, shareholders approved a change to the Company’s authorized share capital to establish a dual class share structure by (i) creating a new class of shares consisting of unlimited Class B Ordinary Shares, which entitle the holder to fifty (50) votes per Class B Ordinary Share on any resolution of shareholders, and (ii) designating the Company’s existing Ordinary Shares as Class A Ordinary Shares, each with no par value (the “Share Re-classification”). The Share Re-classification became effective upon filing of the Amended and Restated Memorandum and Articles of Association with the Companies Registry of the British Virgin Islands by the Company. The Company is authorized to issue an unlimited number of shares, divided into two Classes consisting of Class A Ordinary Shares with no par value and Class B Ordinary Shares with no par value.

Upon the effectuation of the Share Re-classification, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Re-classification.  Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.

About China SXT Pharmaceuticals, Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Safe Harbor Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. The Company’s actual results may differ materially from those expressed in any forward-looking statements as a result of various factors and uncertainties. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company’s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Feng Zhou, Chief Executive Officer

Email: fzhou@sxtchina.com

FAQ

What change did China SXT Pharmaceuticals (SXTC) make on March 24, 2026?

SXTC implemented a share re-classification and began trading Class A Ordinary Shares under SXTC. According to the company, the amended charter created unlimited Class B shares and redesignated existing shares as Class A, effective upon filing with the BVI Companies Registry.

What voting rights do Class B Ordinary Shares deliver for SXTC shareholders?

Class B Ordinary Shares carry 50 votes per share, giving them substantially greater voting power. According to the company, the dual-class structure was approved July 28, 2025 and became effective when the amended memorandum and articles were filed in the British Virgin Islands.

Will nominee-held SXTC shares be adjusted after the re-classification?

Yes, shares held through banks, brokers or nominees will be automatically adjusted to reflect the re-classification. According to the company, beneficial holders should contact their bank, broker or nominee for details and any questions about the adjustment.

How can SXTC shareholders get help with the share re-classification process?

Shareholders should contact their bank, broker or the transfer agent, Transhare Corporation, for assistance. According to the company, Transhare can be reached at +1 303-662-1122 for transfer-agent related questions about the re-classification.

When was the dual-class structure for SXTC approved by shareholders?

Shareholders approved the dual-class share structure at a special meeting on July 28, 2025. According to the company, that vote authorized creation of unlimited Class B shares and redesignation of existing shares as Class A Ordinary Shares.